Value-based care pays the provider to keep people healthy, not to bill more encounters. When the incentive aligns with the patient's long-term health, the model works. The bet is right. What no one built is the data layer it has to run on.
It is like navigating by the last known position of a ship. The position is accurate. It is just not now. By the time claims show a patient's trajectory bending, they have been admitted. The cost is spent. The window is gone.
Agilon managed hundreds of thousands of patients with a real data stack: claims fused with partner-practice records. The cost trend still formed where neither could see it, between visits and outside the primary-care walls. Management caught it only in December 2023. Not bad strategy. A structural blindspot in the data they had.
This is the lesson of the 2022–2024 value-based reset. Bright Health, Clover, Cano, Agilon: different proximate causes, one shared exposure. Each was accountable for cost and risk it could not see early enough to manage, least of all what was happening to patients between visits.
A patient with congestive heart failure doesn't deteriorate in front of a clinician. They deteriorate on a Tuesday afternoon, at home, when their resting heart rate climbs and their step count drops.
That signal exists, and it is flowing now, from the wrist of roughly a third of American adults, and from the home blood-pressure cuffs, scales, and pulse oximeters that reach the older patients a wristband misses. The question is whether the entity financially accountable for what happens next is looking at it.
Clinical AI now reads continuous longitudinal biosignal at scale, flagging the precursors to an acute event days before symptoms surface, for a clinician to confirm and act on.
Wearable adoption crossed a third of adults, reimbursable home monitors reached the older patients a wristband misses, and information-blocking rules forced the first real wave of FHIR APIs into production, so the clinical record is finally queryable to fuse the live signal against it.
None of this held together before 2024, and the window won't stay open long.
We turn continuous between-visit signal into cost-trend intelligence: fused with the clinical record, ranked by care-plan context, surfaced in the workflows of providers that carry real financial accountability for what the signal is telling them.
Not a better dashboard on the same old data. A different data substrate that makes value-based care's original promise workable.
We're early, the team is small, and the problem is hard. We turn continuous between-visit signal into cost-trend intelligence providers can act on. If clinical AI, wearables and remote monitoring, or value-based care is your world, let's talk.